Hanmi Science

한미사이언스 · 008930

Financials Diversified Financials · KOSPI

Large-cap

Market cap US$1.6B (₩2.2T)

Overview

Hanmi Science is a holding company, listed on KOSPI (Korea's main stock exchange), that earns income through dividends from its subsidiaries, patent and trademark royalties, a healthcare business, and a pharmaceutical wholesale operation.

Its healthcare arm develops and distributes medical devices, consumer health products, beauty-care items, and pharmacy-focused IT software. Its wholesale division supplies medicines, health supplements, and pharmacy equipment to pharmacies and hospitals through both a dedicated online platform and a nationwide sales network.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$983.3M

▲ +5.7% YoY

Operating profit · FY2025

US$100.5M

▲ +40.3% YoY

Net income · FY2025

US$85.3M

▲ +107.6% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$904.3M(₩1.2T)	US$930M(₩1.3T)	US$983.3M(₩1.4T)
Operating profit	US$90.2M(₩124.5B)	US$71.6M(₩98.9B)	US$100.5M(₩138.7B)
Net income	US$83.4M(₩115.1B)	US$41.1M(₩56.7B)	US$85.3M(₩117.7B)

Revenue

FY2023US$904.3M
FY2024US$930M
FY2025US$983.3M

Operating profit

FY2023US$90.2M
FY2024US$71.6M
FY2025US$100.5M

Net income

FY2023US$83.4M
FY2024US$41.1M
FY2025US$85.3M

Key ratios (FY2025)

ROE

12.3%

Debt/Eq

55.2%

Op. margin

10.2%

Net margin

8.7%

Rev. YoY

▲ +5.7%

Why it matters

As an operating holding company, it generates its own revenues directly, not solely through dividends, while also coordinating long-term strategy and sharing risk across new-drug development within its group.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?